PECS-2 for Breast Surgery

Summary

There is no consensus regarding which alternative is the best anesthesia for breast surgery, general anesthesia and morphine for postoperative analgesia or a combination of regional anesthesia and general anesthesia that possibly attenuates or abolishes the need for morphine.

The current study aims to determine which of the two strategies that is best in relation to postoperative pain, nausea and risk of recurrence of the disease.

Conditions

• Breast Neoplasm Female
• Regional Anesthesia
• Anesthesia
• Regional Anesthesia Morbidity
• Anesthesia Morbidity

Interventions

DRUG

Ropivacaine 5 mg/ml, 35 ml

Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.

DRUG

Remifentanil 50 microg/ml

The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.

DRUG

Betamethason 4 mg

Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.

DRUG

Paracetamol 1,5 g

Administered preoperatively to prevent pain postoperatively.

DRUG

Propofol

The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.

DRUG

Arcoxia, 120 mg

Administered preoperatively to prevent pain postoperatively.

DRUG

Ondansetron 4 mg

Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.

DRUG

Morphine

Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.

Sponsors & Collaborators

• Umeå University

  lead OTHER

Principal Investigators

• Joakim Johansson, PhD · Umea University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-05-23

Primary Completion

2020-10-22

Completion

2020-10-22

Countries

• Sweden

Study Locations